Search hospitals > Idaho > Sandpoint
Kootenai Cancer Clinic
Claim this profileSandpoint, Idaho 83864
Global Leader in Cancer
Global Leader in Breast Cancer
Conducts research for Lung Cancer
Conducts research for Recurrence
Conducts research for Non-Small Cell Lung Cancer
226 reported clinical trials
2 medical researchers
Summary
Kootenai Cancer Clinic is a medical facility located in Sandpoint, Idaho. This center is recognized for care of Cancer, Breast Cancer, Lung Cancer, Recurrence, Non-Small Cell Lung Cancer and other specialties. Kootenai Cancer Clinic is involved with conducting 226 clinical trials across 399 conditions. There are 2 research doctors associated with this hospital, such as John M. Schallenkamp and Benjamin T. Marchello.Area of expertise
1Cancer
Global LeaderStage IV
Stage III
Stage II
2Breast Cancer
Global LeaderStage IV
HER2 negative
ER positive
Top PIs
John M. SchallenkampBenefis Healthcare- Sletten Cancer Institute4 years of reported clinical research
Expert in Cancer
Expert in Lung Cancer
177 reported clinical trials
254 drugs studied
Benjamin T. MarchelloKalispell Regional Medical Center8 years of reported clinical research
Studies Breast Cancer
Studies Ovarian Cancer
6 reported clinical trials
20 drugs studied
Clinical Trials running at Kootenai Cancer Clinic
Breast Cancer
Cancer
Non-Small Cell Lung Cancer
Lung Cancer
Bladder Cancer
Colon Cancer
Colorectal Cancer
Ovarian Cancer
Oropharyngeal Carcinoma
Laryngeal Cancer
Chemotherapy + Hormone Therapy
for Breast Cancer
This Phase III Trial will determine whether adjuvant chemotherapy (ACT) added to ovarian function suppression (OFS) plus endocrine therapy (ET) is superior to OFS plus ET in improving invasive breast cancer-free survival (IBCFS) among premenopausal, early- stage breast cancer (EBC) patients with estrogen receptor (ER)-positive, HER2-negative tumors and 21-gene recurrence score (RS) between 16-25 (for pN0 patients) and 0-25 (for pN1 patients).
Recruiting2 awards Phase 319 criteria
Carvedilol
for Preventing Heart Problems in HER2 Positive Breast Cancer
This study is evaluating whether a drug used to treat high blood pressure and heart failure may help prevent heart damage in patients with breast cancer.
Recruiting2 awards Phase 323 criteria
Shorter Chemo-Immunotherapy Without Anthracyclines
for Breast Cancer
This phase III trial compares the effects of shorter chemotherapy (chemo)-immunotherapy without anthracyclines to usual chemo-immunotherapy for the treatment of early-stage triple negative breast cancer. Paclitaxel is in a class of medications called anti-microtubule agents. It stops cancer cells from growing and dividing and may kill them. Carboplatin is in a class of medications known as platinum-containing compounds. It works in a way similar to the anticancer drug cisplatin, but may be better tolerated than cisplatin. Carboplatin works by killing, stopping or slowing the growth of cancer cells. Cyclophosphamide is in a class of medications called alkylating agents. It works by damaging the cell's deoxyribonucleic acid (DNA) and may kill cancer cells. It may also lower the body's immune response. Docetaxel is in a class of medications called taxanes. It stops cancer cells from growing and dividing and may kill them. Doxorubicin is an anthracycline chemotherapy drug that damages DNA and may kill cancer cells. Pembrolizumab may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Shorter treatment without anthracycline chemotherapy may work the same as the usual anthracycline chemotherapy treatment for early-stage triple negative breast cancer.
Recruiting2 awards Phase 347 criteria
Similar Hospitals nearby
Select from list below to view details
Frequently asked questions
What kind of research happens at Kootenai Cancer Clinic?
Kootenai Cancer Clinic is a medical facility located in Sandpoint, Idaho. This center is recognized for care of Cancer, Breast Cancer, Lung Cancer, Recurrence, Non-Small Cell Lung Cancer and other specialties. Kootenai Cancer Clinic is involved with conducting 226 clinical trials across 399 conditions. There are 2 research doctors associated with this hospital, such as John M. Schallenkamp and Benjamin T. Marchello.